Welcome to our dedicated page for Cannabis Bioscience International Holdings news (Ticker: CBIH), a resource for investors and traders seeking the latest updates and insights on Cannabis Bioscience International Holdings stock.
About Cannabis Bioscience International Holdings Inc (CBIH)
Cannabis Bioscience International Holdings Inc (CBIH) is an innovative biotechnology company that pioneers the integration of cannabinoid therapies and advanced pharmaceutical research to develop novel treatment methodologies. Specializing in the exploration of alternative therapies, CBIH is deeply engaged in researching and patenting cannabinoid-based treatments aimed at addressing critical medical conditions such as cancer, inflammatory diseases, and neurodegenerative disorders. The company’s focused efforts in leveraging the antitumor, anti-inflammatory, antiviral, and neuroprotective properties of cannabinoids underscore its commitment to advancing market knowledge in both the cannabis and medical research sectors.
Core Business and Research Initiatives
At its core, CBIH invests in a robust research and development program that emphasizes patent innovation and intellectual property protection. The company employs a seasoned team of researchers, scientists, and legal experts to develop utility patents that detail novel treatment approaches for breast and pancreatic cancers, herpes zoster, knee osteoarthritis, and multiple other conditions. This proactive patent filing strategy not only secures unique cannabinoid formulations but also positions CBIH as a key player in a rapidly evolving industry where technology and innovation converge.
Operations and Market Position
Operating primarily on the OTC Markets, CBIH combines deep scientific expertise with strategic legal and business methodologies to differentiate its offerings in the competitive field of medical cannabis research. The company’s operations extend beyond research, as it actively seeks strategic alliances and merger opportunities designed to enhance its market reach and diversify its revenue streams. With a distinctive focus on clinical trials and regulatory engagement, including participation in DEA hearings related to cannabis reclassification, CBIH demonstrates a commitment to maintaining and expanding its influence in both the healthcare and cannabis sectors.
Strategic Innovation through Intellectual Property
Central to CBIH’s business model is its emphasis on securing intellectual property through a continued stream of patent applications. This dynamic approach not only safeguards the company’s innovations but also enhances its attractiveness to pharmaceutical and biotech collaborators. By integrating advanced biotechnological techniques and artificial intelligence in its research processes, CBIH builds a sustainable competitive advantage that underpins its long-standing value proposition in the development of cannabinoid-based therapeutics.
Commitment to Research and Global Health Initiatives
CBIH’s commitment to science is further highlighted by its strategic investments in building a diverse and highly qualified research team. The company actively recruits specialized medical professionals, including oncologists and cardiologists, to bolster its clinical research capabilities. This multidisciplinary approach, combined with robust patent strategies and development of proprietary research guides for intellectual property management, reinforces CBIH’s role as an influential player in medical innovation and biotechnology.
Industry Impact and Collaborative Efforts
In the broader industry ecosystem, Cannabis Bioscience International Holdings serves as a catalyst for change. The company’s endeavors have significant implications for the medical community, especially as it champions the therapeutic benefits of cannabinoids. By creating pathways for advanced research and facilitating key partnerships with healthcare institutions, CBIH contributes to a deeper understanding of cannabis as a viable option in modern medicine. Importantly, the company’s informational outreach also emphasizes education and transparency, fostering a connected community of scientists, patients, and industry experts.
Frequently Asked Questions about CBIH
- What is the primary focus of CBIH?
CBIH is dedicated to advancing cannabinoid-based therapies through rigorous research and patent development, focusing on innovative treatments for various medical conditions.
- How does CBIH generate revenue?
The company primarily generates revenue by advancing its patent portfolio, developing proprietary cannabinoid formulations, and pursuing strategic partnerships in the pharmaceutical and biotech sectors.
- What areas of research does CBIH specialize in?
CBIH specializes in the development of therapeutic methodologies for diseases such as cancer, inflammatory conditions, and neurodegenerative disorders through the use of cannabinoid compounds.
- How does the company maintain its competitive edge?
Through its robust intellectual property strategy, continuous research and development efforts, and strategic recruitment of top-tier medical specialists, CBIH sustains its competitive advantage in the market.
- What distinguishes CBIH from other cannabis-related companies?
Unlike many companies in the industry, CBIH integrates advanced scientific research with a strong focus on intellectual property protection, ensuring its innovations are both novel and marketable.
- How does CBIH's research impact global healthcare initiatives?
By developing innovative cannabinoid treatments and facilitating clinical research partnerships, CBIH contributes to advancing medical knowledge and offering new therapeutic options for underserved medical conditions.
- What role does the legal team play at CBIH?
The legal team is instrumental in securing and protecting the company’s intellectual property, ensuring that patents and proprietary research are effectively managed to support long-term growth.
- How is CBIH involved in regulatory and reclassification efforts?
CBIH actively engages in discussions and hearings regarding the reclassification of cannabis, aiming to foster a regulatory environment that supports advanced research and the development of clinically proven therapies.
CBIH has announced that Brian Cuban, Esq., a notable attorney, best-selling author, and mental health advocate, has joined their Reclassification Team. Cuban will represent CBIH at the DEA hearings on marijuana rescheduling. He brings a unique blend of personal recovery experience and professional advocacy. Cuban, a graduate of Penn State University and The University of Pittsburgh School of Law, has been a vocal champion for individuals facing addiction and mental health challenges. His notable works include 'The Addicted Lawyer' and 'Body Brokers.'
Rosangel Andrades, CBIH R&D Director, praised Cuban's addition, emphasizing the company's commitment to reclassification efforts. Cuban's extensive legal background, with over two decades of experience, makes him a valuable asset in constructing evidence-based arguments for rescheduling marijuana. The reclassification aims to address marijuana's current Schedule I designation under the Controlled Substances Act (CSA), which contradicts modern scientific understanding.
CBIH is dedicated to presenting robust scientific evidence on marijuana's medical benefits, advocating for its reclassification to improve access to treatments for chronic pain, cancer, epilepsy, PTSD, anxiety, and more.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) has announced a significant partnership with Stephen Gould, a company known for its robust global network and expertise in manufacturing and distribution. This collaboration aims to enhance the delivery of CBIH’s advanced medical product line. Stephen Gould, with over 80 years of experience and operations in more than 40 locations across six countries, brings a wealth of knowledge and a prestigious client portfolio including Walmart, The Children’s Place, GoPro, and Verizon.
According to CBIH’s R&D Director, Rosangel Andrades, this partnership will expedite the market delivery of CBIH's innovative formulations. CBIH will provide its proprietary medical formulations, while Stephen Gould will handle manufacturing and distribution. The first wave of products is expected to launch in the first quarter of 2025.
This partnership is a strategic move for CBIH, aiming to improve market reach and operational efficiency, reaffirming its commitment to delivering quality, science-driven medical solutions.
Cannabis Bioscience International Holdings (CBIH) has filed a petition to include Alexis Bortell as a witness in the upcoming DEA hearing on marijuana rescheduling, scheduled for February 4th. Bortell, diagnosed with intractable epilepsy at age seven, found relief through CBD and THC after conventional treatments failed. Her alternatives were either Felbatol, a drug with serious side effects, or a risky brain surgery.
The company aims to demonstrate through Bortell's testimony that cannabis' Schedule I classification is inappropriate, as it implies no medical use. The current classification has Bortell's career opportunities in medical school and created barriers to accessing her medication, despite keeping her seizure-free for nearly a decade.
Cannabis Bioscience International Holdings (CBIH) CEO Dante Picazo represented the company at DEA Hearing Docket No. 1362 and 24-44 regarding cannabis reclassification. The hearings involve 20 groups debating the potential rescheduling of cannabis from Schedule I to Schedule III. The proposed change could enable advanced medical research, treatment development, and economic growth.
CBIH is seeking expert witnesses, including patients with multiple sclerosis and epilepsy, medical experts, and legal professionals, to participate in the next DEA Hearing. The deadline for participation is December 11, 5:00 PM CT. The company emphasizes that failure to achieve reclassification could delay further discussions for 8-10 years.
Cannabis Bioscience International Holdings (CBIH) participated in a DEA hearing on cannabis reclassification in Arlington, Virginia. CEO Dante Picazo presented a 78-page statement supporting the reclassification of cannabis from its current Schedule I status. The company argues that reclassification would bridge science, policy, and opportunity gaps, potentially leading to economic growth, job creation, and advancement in medical research. A final verdict is expected within two to three months following extensive deliberation. CBIH emphasizes that reclassification would enable responsible medical use and resolve long-standing legal ambiguities.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) announces the development of the Rejuvenescence Chip, a revolutionary anti-aging device that combines phytocannabinoids and gestrinone. The company holds 13 patents and continues expanding its intellectual property portfolio. The chip offers controlled release of active ingredients for aesthetic, hormonal, and sexual health benefits. Features include improved skin elasticity, reduced fat accumulation, increased muscle mass, hormonal regulation, and enhanced sexual well-being. Dr. Jennifer Salguero explains that treatment requires blood analysis for personalized hormone and endocannabinoid formulation.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is strengthening its clinical research team ahead of launching specialized pharmaceutical and nutraceutical cannabinoid products. The company has filed 13 medical patents with the USPTO and expanded its R&D division with notable additions including Dr. Stephanie Hartmann, Dr. Yesiree Baptista, and experts in microbiology, immunology, and pharmacy. CBIH is focusing on developing mRNA vaccines for cancer and other diseases, utilizing molecular biology, nuclear medicine, and advanced technologies. The company aims to capitalize on potential cannabis reclassification from Schedule I to Schedule III and position itself as an attractive partner for larger pharmaceutical firms.
Cannabis Bioscience International Holdings (CBIH) has been selected to participate in the DEA hearings on marijuana rescheduling. CEO Dante Picazo will present clinical trial data demonstrating cannabis's therapeutic benefits. The company will provide evidence on safety and efficacy of cannabis compounds while highlighting economic opportunities from rescheduling.
According to Grand View Research, the U.S. cannabis market was valued at $33.6 billion in 2023, with projected growth of 12.1% annually from 2024 to 2030. CBIH, with ten patent submissions, focuses on developing treatments for conditions including cancer, epilepsy, neurodegenerative diseases, and osteoarthritis.
Cannabis Bioscience International Holdings (CBIH) has appointed Charles Tamburello to its board of directors. With nearly three decades of experience in public markets, Tamburello brings extensive M&A expertise and strategic insights to CBIH. As owner-operator of Global Discovery Group, he has helped hundreds of public and private companies since 1995. His appointment aims to strengthen CBIH's M&A strategy, enhance capital acquisition capabilities, and drive sustainable growth. The company expects his industry connections and expertise to facilitate identifying acquisition targets and maximizing deal success.
Cannabis Bioscience International Holdings (CBIH) has significantly expanded its patent portfolio by filing six utility non-provisional applications for cannabinoid-based therapies. The patents cover treatments for pancreatic cancer, breast cancer, herpes zoster, menopause, knee osteoarthritis, and COVID-19/Influenza. Under the guidance of newly appointed patent attorney Mauricio Ávila, CBIH filed five patents in just five weeks and aims to file more than 15 patents by year-end. The company has also developed a Patent Application Filing Guide for the U.S. market, strengthening its position for potential strategic alliances with major pharmaceutical companies.
FAQ
What is the current stock price of Cannabis Bioscience International Holdings (CBIH)?
What is the market cap of Cannabis Bioscience International Holdings (CBIH)?
What is Cannabis Bioscience International Holdings Inc (CBIH) focused on?
How does CBIH differentiate itself in the competitive biotechnology landscape?
What kind of medical conditions is CBIH targeting with its research?
How does CBIH leverage its intellectual property in its business model?
What is the role of clinical research in CBIH's operations?
How does CBIH address regulatory challenges in the cannabis industry?
What are the strategic benefits of CBIH's patent filings?
How does CBIH support its research and development initiatives?
